Advantech Capital, a China-focused private equity fund, has led a Series B financing round of more than US$100 million for China-based biopharmaceutical company Zai Lab. Healthcare-focused investment firm OrbiMed Advisors and existing investors, venture capital firms Qiming Ventures, Sequoia Capital China and TF Capital, also participated in the round. Zai Lab intends to use the new capital to support its research and development programs.